Abstract

In the present study, Saccharomyces cerevisiae was employed to fabricate silver nanoparticles (AgNPs) as a sustainable and ecofriendly approach. The mycofabricated AgNPs were found to be spherical with a Z-average size of 29.07 nm and zeta potential of −16 mV. This study focused on the biological properties of fungus-mediated fabrication of AgNPs. The AgNPs ascertained significant antibacterial activity against Listeria monocytogenes and Serratia marcescens with minimum inhibitory concentration (MIC) of 4 and 2 µg mL−1 and minimum bactericidal concentration (MBC) of 16 and 16 µg mL−1, respectively. Besides, the AgNPs at the studied concentrations ascertained significantly higher biofilm inhibitory and degradation activity against S. marcescens compared to the reference antibiotic drug gentamicin (P < 0.05). In contrast, gentamicin at the studied concentrations exhibited significantly higher biofilm inhibitory and degradation activity against L. monocytogenes compared to AgNPs (P < 0.05). Moreover, Flow cytometry analysis exhibited dose-dependent antibacterial properties for both AgNPs and gentamicin against both S. marcescens and L. monocytogenes. Furthermore, the AgNPs ascertained a dose-dependent antioxidant activity with a maximum 65.75 ± 2.70 % at the concentration of 500 µg mL−1. Impressively, the AgNPs at the concentration of 500 µg mL−1 represented anticoagulant performance with PT and aPTT values of 21.80 ± 3.31 and 70.57 ± 2.25 s, respectively. Additionally, the AgNPs at the concentration of 500 µg mL−1 showed 19.48 ± 3.82 % thrombolysis and 64.74 ± 1.63 % alpha-amylase inhibition. The AgNPs also ascertained a maximum 38.26 ± 1.70 % glucose uptake inhibition by S. cerevisiae at a concentration of 1000 µg mL−1. Overall, the above-mentioned unique physicochemical and biological properties of AgNPs made them attractive for biomedicine.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call